Clinical Trial Detail

NCT ID NCT02966353
Title Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

myelofibrosis

Therapies

Ruxolitinib

Age Groups: adult senior

No variant requirements are available.